A decision-ready blueprint
A governed strategy and digital architecture designed around the commercial realities of cell & gene therapy developers.
Scientific, commercial, and digital architecture, with specialist expertise assembled where the engagement requires it.
Governed architecture model
A principal-led model that connects source context, configured systems, review ownership, and practical delivery for cell & gene therapy developers.
Cell and gene therapy leaders rarely lack data. The harder problem is deciding which scientific, clinical, CMC, and commercial evidence should inform the next portfolio, development, or partnering decision. Lonrú Consulting designs governed digital architecture that makes those relationships visible without flattening the scientific context that gives them meaning.
The objective is a practical decision environment: defined source systems, clear review ownership, and interfaces that make the current question easier to answer. An agentic capability can support defined work within that environment, but it is not the starting point.
We define the source inventory, evidence boundaries, permissions, and working instructions for the decision in view. The result is a controlled context that distinguishes current evidence from assumptions, pending review, and external intelligence.
Where useful, configured systems can retrieve, compare, structure, or prepare material from the approved context. Their role is to support a defined workflow, not to replace scientific or commercial judgment.
Lonrú provides principal-led architecture and review governance. Depending on the engagement, review may be led by Lonrú, shared with client subject-matter experts, or assigned to client SMEs for final validation and approval.
Approved outputs are placed in a usable interface such as a portfolio view, decision tracker, evidence map, or executive briefing environment.
Bring together the scientific, development, CMC, clinical, and commercial information relevant to a decision while retaining the source and review context behind each conclusion.
Structure decision criteria, risks, and evidence requirements so that development questions can be reviewed before they become programme delays.
Give leadership a decision surface that can relate clinical milestones, manufacturing constraints, and commercial assumptions without treating them as isolated workstreams.
Clarify who prepares, reviews, challenges, approves, and maintains each decision-ready output.
The first deliverable is not a generic platform. It is an architecture blueprint that identifies the systems of record, integration boundaries, information-security constraints, review model, and outcome that matter for the selected workflow.
Where automation is subsequently appropriate, it is configured around those controls. This keeps the system useful to scientists and operators while giving leadership a credible view of progress, risk, and next actions.
Relevant experience
Preclinical to IND
Created interactive Preclinical-to-IND decision-tree frameworks and risk-mitigation reports to help advanced-therapy enabling-technology companies align product capabilities with FDA IND validation requirements and reduce preclinical translation delays.
NPV modelling
Designed multi-dimensional pricing and Net Present Value modelling systems for cell and gene therapies, integrating clinical-trial milestones, manufacturing COG constraints, and quantified patient-benefit metrics.
Practical questions
Next step
Bring the decision, workflow, or delivery constraint that needs a clearer operating path.
Request a focused briefing